Date:	2022.02.07		<u>•</u>
Your Name:	Yilang Wang		
<b>Manuscript Title:</b>	MiR-448 Suppresses	s Cell Proliferation and Glycolysis of Hepatocellular Carcinoma Through	Inhibiting
<b>IGF-1R Expression</b>	<u>n</u>		
Manuscript numb	per (if known):	JGO-22-90	<u>.</u>
•			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	X_None	

5	Payment or honoraria for lectures, presentations,	XNone		
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	X_None		
	testimony			
7	Support for attending	X_None		
	meetings and/or travel			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	X_None		
	Safety Monitoring Board or			
10	Advisory Board	V None		
10	Leadership or fiduciary role in other board, society,	XNone		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X_None		
12	Receipt of equipment,	X_None		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	XNone		
	financial interests			
PIE	ease summarize the above c	onflict of interest in the fo	pilowing pox:	
	I have no conflicts of interest to declare.			

have no conflicts of interest to declare.	

Date:	2022.02.07		<u>•</u>
Your Name:	Xiaohong Chen		•
Manuscript Title:	MiR-448 Suppresses	s Cell Proliferation and Glycolysis of Hepatocellular Carcinoma Throu	igh Inhibiting
<b>IGF-1R Expression</b>			
Manuscript numb	er (if known):	JGO-22-90	<u>•</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone		
6	Payment for expert testimony	X_None		
7	Support for attending meetings and/or travel	XNone		
	Datasta planned issued as	V. Nana		
8	Patents planned, issued or pending	X_None		
ļ	Fe			
9	Participation on a Data	X_None		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	X_None		
12	Receipt of equipment, materials, drugs, medical	XNone		
ļ	writing, gifts or other services			
13	Other financial or non-	X_None		
	financial interests			
	Please summarize the above conflict of interest in the following box:			

Date:	2022.02.07		<u>.</u>
Your Name:	Ninghua Yao		•
Manuscript Title: M	liR-448 Suppresses	Cell Proliferation and Glycolysis of Hepatocellular Carcinoma Through	Inhibiting
IGF-1R Expression			
Manuscript numbe	r (if known):	JGO-22-90	<u>.</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone		
6	Payment for expert testimony	X_None		
7	Support for attending meetings and/or travel	XNone		
	Datasta planned issued as	V. Nana		
8	Patents planned, issued or pending	X_None		
ļ	Fe			
9	Participation on a Data	X_None		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	X_None		
12	Receipt of equipment, materials, drugs, medical	XNone		
ļ	writing, gifts or other services			
13	Other financial or non-	X_None		
	financial interests			
	Please summarize the above conflict of interest in the following box:			

Date:	2022.02.07	•
Your Name:	un Gong	
Manuscript Title: <u>Mi</u>	R-448 Suppresses Cell Proliferation and	Glycolysis of Hepatocellular Carcinoma Through Inhibiting
IGF-1R Expression		
Manuscript number	if known):JGO-22-90	<u>.</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	l	Time frame: Since the initial	planning of the work
1	All support for the present	X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	ivo time innit for this item.		
		<b>Time for a second</b>	2C
2		Time frame: past	36 months
2	Grants or contracts from	X_None	
	any entity (if not indicated		
2	in item #1 above).	Y N	
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone			
6	Payment for expert testimony	X_None			
7	Support for attending meetings and/or travel	XNone			
	Datasta planned issued as	V. Nana			
8	Patents planned, issued or pending	X_None			
ļ	Fe				
9	Participation on a Data	X_None			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society, committee or advocacy group, paid or unpaid				
11	Stock or stock options	X_None			
12	Receipt of equipment, materials, drugs, medical	XNone			
ļ	writing, gifts or other services				
13	Other financial or non-	X_None			
	financial interests				
	Please summarize the above conflict of interest in the following box:				

Date:	2022.02.07		<u>•</u>
Your Name:	Yongfeng Cao		•
Manuscript Title: I	MiR-448 Suppresses	s Cell Proliferation and Glycolysis of Hepatocellular Carcinoma Thro	ugh Inhibiting
<b>IGF-1R Expression</b>			
Manuscript number	er (if known):	JGO-22-90	<u> </u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	l	Time frame: Since the initial	planning of the work
1	All support for the present	X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	ivo time innit for this item.		
		<b>Time for a second</b>	2C
2		Time frame: past	36 months
2	Grants or contracts from	X_None	
	any entity (if not indicated		
2	in item #1 above).	Y N	
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone			
6	Payment for expert testimony	X_None			
7	Support for attending meetings and/or travel	XNone			
	Datasta planned issued as	V. Nana			
8	Patents planned, issued or pending	X_None			
ļ	Fe				
9	Participation on a Data	X_None			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society, committee or advocacy group, paid or unpaid				
11	Stock or stock options	X_None			
12	Receipt of equipment, materials, drugs, medical	XNone			
ļ	writing, gifts or other services				
13	Other financial or non-	X_None			
	financial interests				
	Please summarize the above conflict of interest in the following box:				

Date:	2022.02.07		<u>.</u>
Your Name:	Xiaoqing Su		,
<b>Manuscript Title:</b>	MiR-448 Suppresse	s Cell Proliferation and Glycolysis of Hepatocellular Carcinoma Through	Inhibiting
<b>IGF-1R Expression</b>	<u>1</u>		
Manuscript numb	er (if known):	JGO-22-90	<u>.</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone			
6	Payment for expert testimony	X_None			
7	Support for attending meetings and/or travel	XNone			
	Datasta planned issued as	V. Nana			
8	Patents planned, issued or pending	X_None			
ļ	Fe				
9	Participation on a Data	X_None			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society, committee or advocacy group, paid or unpaid				
11	Stock or stock options	X_None			
12	Receipt of equipment, materials, drugs, medical	XNone			
ļ	writing, gifts or other services				
13	Other financial or non-	X_None			
	financial interests				
	Please summarize the above conflict of interest in the following box:				

Date:	2022.02.07		•
Your Name:	Xiu Feng		
Manuscript Title:	MiR-448 Suppresses	s Cell Proliferation and Glycolysis of Hepatocellular Carcinoma Thro	ough Inhibiting
IGF-1R Expression			
Manuscript numb	er (if known):	JGO-22-90	
·	• -		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	l	Time frame: Since the initial	planning of the work
1	All support for the present	X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	ivo time innit for this item.		
		<b>Time for a second</b>	2C
2		Time frame: past	36 months
2	Grants or contracts from	X_None	
	any entity (if not indicated		
2	in item #1 above).	Y N	
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

5	Payment or honoraria for lectures, presentations,	XNone				
	speakers bureaus, manuscript writing or educational events					
6	Payment for expert testimony	XNone				
7	Support for attending meetings and/or travel	XNone				
	meetings und/or travel					
8	Patents planned, issued or	XNone				
	pending					
9	Participation on a Data	X None				
	Safety Monitoring Board or Advisory Board					
10	Leadership or fiduciary role	XNone				
	in other board, society,					
	committee or advocacy group, paid or unpaid					
11	Stock or stock options	X_None				
12	Receipt of equipment,	XNone				
	materials, drugs, medical					
	writing, gifts or other services					
13	Other financial or non-	XNone				
	financial interests					
	Please summarize the above conflict of interest in the following box:					

Date:	2022.02.0	7			<u>•</u>
Your Name:	Min Tao				•
Manuscript Title	: MiR-448 Suppress	es Cell Proliferation and	d Glycolysis of Hepat	ocellular Carcinoma	Through Inhibiting
IGF-1R Expressio	<u>on</u>				
Manuscript num	ber (if known):	JGO-22-90			
•	· • • • • • • • • • • • • • • • • • • •				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	X_None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,	_	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X_None	
	D	V N	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Please summarize the above conflict of interest in the following box:			